A Study of MRG003 in Combination With Pucotenlimab Versus Chemotherapy in the Treatment of Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

NCT06976190 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

446

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent or Metastatic Nasopharyngeal Carcinoma

Interventions

DRUG: MRG003 + Pucotenlimab
DRUG: Gemcitabine, Docetaxel, or Capecitabine

Sponsor

Shanghai Miracogen Inc.